Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Delaying RT for higher-risk prostate cancer found safe

Key clinical point: It appears safe to delay the start of radiation therapy by up to 6 months after the start of androgen deprivation therapy for higher-risk prostate cancer.

Major finding: The 10-year overall survival did not differ significantly whether radiation therapy was initiated before starting androgen deprivation therapy or 1-60 days after starting ADT (hazard ratios, 1.03 in the unfavorable intermediate-risk group and 1.07 in the high-risk/very-high-risk group), 61-120 days after starting ADT (HRs, 0.95 and 1.04, respectively), or 121-180 days after starting ADT (HRs, 0.99 and 1.07, respectively).

Study details: A retrospective study of 63,858 men with prostate cancer diagnosed during 2004-2014 and managed with external beam radiation therapy and ADT.

Disclosures: The study was funded by the National Institutes of Health. The authors disclosed various grants and personal fees outside the submitted work.


Dee EC et al. JAMA Oncol. 2020 Aug 13. doi: 10.1001/jamaoncol.2020.3545.